AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) EVP Joseph Vittiglio sold 770 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $20.80, for a total transaction of $16,016.00. Following the completion of the sale, the executive vice president now directly owns 32,635 shares of the company’s stock, valued at $678,808. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded down $0.25 on Wednesday, hitting $19.85. The stock had a trading volume of 922,792 shares, compared to its average volume of 1,321,663. AMAG Pharmaceuticals, Inc. has a 12 month low of $11.93 and a 12 month high of $24.85. The company has a quick ratio of 1.60, a current ratio of 1.74 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $697.12, a PE ratio of -3.50 and a beta of 0.28.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.68. The company had revenue of $158.30 million during the quarter, compared to analysts’ expectations of $158.84 million. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. AMAG Pharmaceuticals’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.31) earnings per share. equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post -3.33 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Balter Liquid Alternatives LLC bought a new position in AMAG Pharmaceuticals in the fourth quarter worth $120,000. Cambridge Investment Research Advisors Inc. acquired a new position in AMAG Pharmaceuticals during the fourth quarter worth $161,000. Teacher Retirement System of Texas acquired a new position in AMAG Pharmaceuticals during the fourth quarter worth $162,000. Hartford Investment Management Co. acquired a new position in AMAG Pharmaceuticals during the third quarter worth $186,000. Finally, Two Sigma Securities LLC acquired a new position in AMAG Pharmaceuticals during the fourth quarter worth $187,000.
A number of research firms have commented on AMAG. B. Riley upped their price objective on shares of AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday. Cantor Fitzgerald reiterated a “hold” rating and issued a $17.00 target price on shares of AMAG Pharmaceuticals in a report on Tuesday, February 27th. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Jefferies Group downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $21.00 to $20.00 in a report on Monday, March 5th. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $23.91.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) EVP Sells $16,016.00 in Stock” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://ledgergazette.com/2018/03/14/joseph-vittiglio-sells-770-shares-of-amag-pharmaceuticals-inc-amag-stock.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.